Future perspectives for personalized immunotherapy in renal cell carcinoma.

about

Immunotherapy in renal cell carcinoma: latest evidence and clinical implications.

P2860

Q55101776-7FC3B6B1-9F3F-4E3F-AC8F-88E7D77C4D13

P2860

Future perspectives for personalized immunotherapy in renal cell carcinoma.

Item

http://www.wikidata.org/entity/Q38673583

description

2017 nî lūn-bûn

@nan

2017年の論文

@ja

2017年論文

@yue

2017年論文

@zh-hant

2017年論文

@zh-hk

2017年論文

@zh-mo

2017年論文

@zh-tw

2017年论文

@wuu

2017年论文

@zh

2017年论文

@zh-cn

name

Future perspectives for personalized immunotherapy in renal cell carcinoma.

@en

type

Item

label

Future perspectives for personalized immunotherapy in renal cell carcinoma.

@en

prefLabel

Future perspectives for personalized immunotherapy in renal cell carcinoma.

@en

P1476

Future perspectives for personalized immunotherapy in renal cell carcinoma

@en

P2093

Chiara Ciccarese

http://www.w3.org/2001/XMLSchema#string

Roberto Iacovelli

http://www.w3.org/2001/XMLSchema#string

P2860

PD-L1 expression in nonclear-cell renal cell carcinoma.

Anti-programmed Cell Death Protein 1 (PD-1) Antibody Nivolumab Leads to a Dramatic and Rapid Response in Papillary Renal Cell Carcinoma with Sarcomatoid and Rhabdoid Features.

Prognostic Role of PD-L1 Expression in Renal Cell Carcinoma. A Systematic Review and Meta-Analysis.

PD-1 and PD-L1 Expression in Renal Cell Carcinoma with Sarcomatoid Differentiation.

Atezolizumab in combination with bevacizumab enhances antigen-specific T-cell migration in metastatic renal cell carcinoma.

Treatment Beyond Progression in Patients with Advanced Renal Cell Carcinoma Treated with Nivolumab in CheckMate 025.

Elements of cancer immunity and the cancer-immune set point.

IMA901, a multipeptide cancer vaccine, plus sunitinib versus sunitinib alone, as first-line therapy for advanced or metastatic renal cell carcinoma (IMPRINT): a multicentre, open-label, randomised, controlled, phase 3 trial.

Renal Cell Carcinoma Programmed Death-ligand 1, a New Direct Target of Hypoxia-inducible Factor-2 Alpha, is Regulated by von Hippel-Lindau Gene Mutation Status.

Nivolumab versus Everolimus in Advanced Renal-Cell Carcinoma.

P304

1049-1052

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

editorial

P356

10.1080/14712598.2017.1339030

http://www.w3.org/2001/XMLSchema#string

P407

English

P433

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P50

Vincenzo Di Nunno

F Massari

P577

2017-06-07T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

28592155

http://www.w3.org/2001/XMLSchema#string

P921

immunotherapy

Future perspectives for personalized immunotherapy in renal cell carcinoma.

about

P2860

P2860

Future perspectives for personalized immunotherapy in renal cell carcinoma.

description

name

type

label

prefLabel

P1433

P1476

P2093

P2860

P304

P31

P356

P407

P433

P478

P50

P577

P698

P921

P356

P1433

P1476

P2093

P2860

P304

P31

P356

P407

P433

P478

P50

P577

P698

P921